DNA Transformation of Leishmania infantum Axenic Amastigotes and Their Use in Drug Screening

DENIS SERENO,† GAÉTAN ROY,1 JEAN LOUP LEMESRE,2 BARBARA PAPADOPOULOU,1 AND MARC OUELLETTE1*

Centre de Recherche en Infectiologie du Centre de Recherche du CHUL and Département de Microbiologie, Faculté de Médecine, Université Laval, Québec, Canada,1 and Laboratoire de Biologie et Immunologie Parasitaire, Centre IRD de Montpellier, Montpellier, France2

Received 18 September 2000/Returned for modification 20 November 2000/Accepted 24 January 2001

Protocols for DNA electroporation in Leishmania promastigote cells are well established. More recently, in vitro culture of axenic Leishmania amastigotes became possible. We have established conditions for DNA transformation of axenically grown Leishmania infantum amastigotes. Parameters for DNA electroporation of Leishmania axenic amastigotes were systematically studied using luciferase-mediated transient transfection. Cell lines expressing stable luciferase activity were then selected, and their ability to be used in an in vitro drug screening procedure was determined. A model was established, using axenic amastigotes expressing luciferase activity, for rapidly determining the activity of drugs directly against both axenic and intracellular amastigotes. For intracellular amastigotes, the 50% effective concentrations of pentamidine, sodium stibogluconate (Pentostam), meglumine (Glucantime), and potassium antimonyl tartrate determined with the luciferase assay were 0.2 μM (0.12 μg/ml), 55 μg/ml, 95 μg/ml, and 0.12 μg/ml, respectively; these values are in agreement with values determined by more labor-intensive staining methods. We also showed the usefulness of luciferase-expressing parasites for analyzing drug resistance. The availability of luciferase-expressing amastigotes for use in high-throughput screening should facilitate the search for new antileishmanial drugs.

Leishmaniasis is a significant cause of morbidity and mortality in several countries of the world (19). A vertebrate host is infected with flagellated extracellular promastigote forms via the bite of a sand fly. Promastigotes are rapidly transformed into nonflagellated amastigotes, which divide actively within the mononuclear phagocytes of the vertebrate host.

The basic treatment for leishmaniasis consists of the administration of sodium stibogluconate (Pentostam), meglumine (Glucantime), or pentamidine. Treatment failure, especially in kala-azar, mucosal leishmaniasis, and diffuse cutaneous leishmaniasis, is becoming a common problem in many areas where the diseases are endemic. There are now strong indications that treatment failure may be partly due to the drug resistance of the parasite (15, 18, 21, 25). In addition, numerous cases of relapse or unresponsiveness have been reported during the treatment of patients coinfected with human immunodeficiency virus and Leishmania spp. (1). Although rapid assays for drug screening of Leishmania promastigotes have been devised (5), promastigotes are usually less sensitive to various drugs than amastigotes (11, 29). Although animal models are well established for drug testing, they are not suitable for large-scale primary drug screens. The development of new drugs has been impeded by the lack of a simple, reliable, and rapid evaluation system allowing the simultaneous determination of drug activity at the mammalian stage under both axenic and intracellular conditions. The development of a system for the in vitro cultivation of amastigotes under axenic conditions enabled the development of models for in vitro drug screening directly on the clinically relevant stage of the parasite (7, 34). However, these systems present some limitations, including the absence of information on the influence of macrophages on drug activity. In order to delineate the potential role played by macrophages in drug toxicity, time-consuming experiments must be carried out using macrophage models like THP-1 (17, 32) or human or mouse monocyte-derived macrophages (3, 4).

The drug screening for several other intracellular pathogens is also complicated by the difficulties in assessing the number of pathogens remaining after drug treatment. The use of reporter genes such as the firefly luciferase, β-galactosidase, or green fluorescent protein gene has considerably facilitated the screening of antimicrobial agents against intracellular pathogens such as Mycobacterium tuberculosis (10, 22), Trypanosoma cruzi (6), and Toxoplasma gondii (26). The same strategy should be of great interest while testing new antileishmanial agents. Protocols for DNA electroporation of Leishmania promastigotes are well established (9), but until now there has been no report of DNA electroporation into axenic Leishmania amastigotes. In this study, we have established conditions for DNA transformation of Leishmania infantum axenic amastigotes. The use of axenic amastigotes stably expressing the firefly luciferase reporter gene for quickly and simultaneously testing drug activity against both axenic and intracellular amastigotes was also evaluated.

MATERIALS AND METHODS

Materials. Meglumine (Glucantime; batch number 331-2), which does not contain m-chlorocresol as a preservative, was supplied by Rhône Poulenc Specia. Sodium stibogluconate (Pentostam; batch number B4131A) from Glaxo-Wellcome was kindly supplied by Chris Carter, University of Strathclyde. Potassium antimonyl tartrate trihydrate, neomycin, hygromycin, phorbol myristate acetate...
Parasites and cultures. A cloned line of *L. infantum* (MHOM/MA/67/ITMAP-263) was used in all experiments. Axenically grown amastigote forms of *L. infantum* were maintained at 37°C with 5% CO₂ by weekly subpassages in a cell-free medium called MAA/20 (medium for axenically grown amastigotes) in 25-ml flasks, as previously described (34). From a starting inoculum of 5 × 10⁵ amastigotes/ml, a cell density of about 5 × 10⁷ parasites/ml was obtained on day 7. MAA/20 consisted of modified medium 199 (Gibco BRL) with Hanks’ balanced salts supplemented with 0.5% soya trypto-casein (Pasteur Diagnostics, Marne la Coquette, France), 0.01 mM bathocuproine disulphonic acid, 3 mM l-cysteine, 15 mM l-glucose, 5 mM l-glutamine, 4 mM NaHCO₃, 0.023 mM bovine hemin, 25 mM HEPES (final pH 6.5), and 20% fetal calf serum (FCS).

Viability test. To estimate the 50% inhibitory concentration of drugs, the MTT micromethod was used as previously described (34). Briefly, axenically grown amastigotes were seeded in a volume of 100 μl in 96-well flat-bottom microtrays. Drugs were added, and after 72 h of incubation 10 μl of MTT (10 mg/ml) was added to each well and plates were further incubated for 4 h. The reaction was then stopped by the addition of 100 μl of 50% isopropanol-10% sodium dodecyl sulfate. The plates were incubated for an additional 30 min under agitation before reading the optical density at 570 nm.

DNA construct and transfection. The pSPaLUC vector used in transient-transfection experiments was made by subcloning the intergenic region of the α-tubulin gene (24) as an EcoRI-BamHI fragment into pSP72 (Promega). The LUC gene was amplified by PCR and subcloned into the BamHI site of vector pSPa filled in by Klenow polymerase to yield pSPaLUC. The vector PSGNeoLUC has been described before (30).

Drug efficacy assay in THP-1. The growth of the luciferase-expressing amastigotes of *L. infantum* in a human leukemia monocyte cell line (THP-1 cells) was evaluated according to the method described by Gebre-Hiwot et al. (17), with modifications. Briefly, THP-1 cells were cultured in RPMI 1640 medium supplemented with 10% FCS, 2 mM glutamine, 100 IU of penicillin/ml, and 100 μg of streptomycin/ml. THP-1 cells in the log phase of growth were differentiated by constant voltage, we introduced by electroporation the plasmid pSPaLUC into the *L. infantum* axenic strain while varying the **H**<sub>I</sub> site of vector PSGNeoLUC that we use routinely to transform promastigotes. Using this constant voltage, we introduced by electroporation the plasmid pSPaLUC into the *L. infantum* axenic strain while varying the capacitance (A) or the DNA concentration (B). The viability of the transfected parasites was measured by the MTT test.

RESULTS

DNA transformation in axenic amastigotes. Transformation of the insect stage of a number of kinetoplastid parasites has already been reported (9). It is also possible to transform *Trypanosoma brucei* bloodstream-form parasites with DNA (8), but no work has been reported yet on DNA transformation of *Leishmania* amastigotes. We have therefore set up the technique to introduce DNA into axenic amastigotes. First, we have attempted to optimize parameters involved in DNA transformation. We used a constant voltage of 450 V, a voltage that we use routinely to transform promastigotes. Using this constant voltage, we introduced by electroporation the plasmid pSPaLUC into the *L. infantum* axenic strain while varying the capacitance (Fig. 1A). Immediately after the shock, cells were put in culture in MAA/20 medium, and after 24 h luciferase activity was measured and the optimal transient-transfection efficiency was found at 750 μF. The transfection efficiency was in close correlation with the survival of the parasites following electroporation (Fig. 1A), with the maximum transfection efficiency observed under conditions leading to 50% survival. We also tested the correlation between the amount of DNA and transformation efficiency, and we found a maximum efficiency while using 20 μg of DNA (Fig. 1B).

Stable transformation of axenic amastigotes. In order to have stable DNA transformation, we tested whether *L. infantum* amastigotes were susceptible to the antibiotics G418 and hygromycin B, the two most widely used drugs selective for
Leishmania transformation. The cells were found to be sensitive to the two antibiotics, with 50% effective concentration (EC50) values of 4 μg/ml for G418 and 17 μg/ml for hygromycin B (Fig. 2). Using optimized conditions established by transient transfection, we have electroporated the plasmid pGMaNEOaLUC (30), which contains the selectable marker for neomycin phosphotransferase (NEO), and the cosmid vector CL-Hyg (31), which contains the hygromycin phosphotransferase (HYG) gene. The selection with the drugs was initiated 24 h after electroporation. The growth of cells highly resistant to G418 was observed after 14 to 20 days, while hygromycin B-resistant cells appeared as quickly as 10 days after the initial electroporation. The transfectants were clearly resistant to the selective drug (Fig. 2). Southern blot analysis of these amastigote transfectants confirmed that both the plasmid pGMaNEOaLUC and the cosmid CL-Hyg were present in several copies (data not shown). Since the pGMaNEOaLUC plasmid contains the luciferase gene, it permitted us to observe a linear correlation between the number of amastigote cells and luciferase activity (Fig. 3). By increasing the concentration of the selective drug, we could increase the copy number of the vector, which led to an even better sensitivity in the detection of the parasite (data not shown).

Use of luciferase-expressing axenic amastigotes in drug screens. For several drugs, the use of axenic amastigotes in drug screens has been found to be superior to the use of promastigotes (7, 34). The linearity between luciferase activity and the number of amastigotes (Fig. 3) prompted us to test whether measuring luciferase activity would permit a rapid determination of drug activity with axenic amastigotes and, even more importantly, with intracellular amastigotes in macrophages. The activity of pentamidine was determined against axenic and intracellular amastigotes and, the EC50s were 1.5 and 0.2 μM, respectively (Fig. 4A). Those values are similar to values reported in the literature while using a laborious staining method for counting the parasites in macrophages (Table 1). Using the luciferase-expressing parasites, we could determine rapidly the EC50 of potassium antimonyl tartrate [Sb(III)] and two pentavalent antimonial compounds, sodium stibogluconate and meglumine for axenic and intracellular amastigotes (Table 1). Values obtained were consistent with values reported in the literature for other methods (Table 1).

In another application of the luciferase marker, we also introduced the pGMaNEOaLUC plasmid into L. infantum R20 (LdiR20), a mutant cell line selected for resistance to potassium antimonyl tartrate (32). We have already shown that this mutant was cross-resistant to meglumine once inside macrophages but not in axenic culture (32). Using the luciferase assay we could easily determine that the LdiR20 amastigote cells were clearly cross-resistant to meglumine once inside macrophages, with an increase in the EC50 from 95 to 330 μg/ml (Fig. 4B).

**DISCUSSION**

The use of reporter genes in a number of intracellular pathogenic microorganisms has facilitated antimicrobial drug discovery and testing (6, 10, 22, 26). Recently, models of axenic Leishmania amastigotes have been introduced and proposed for drug testing, instead of promastigotes (7, 13, 34). In certain models, preservative-free pentavalent antimony was found to be more active against intracellular Leishmania than against axenic amastigotes (32). The evaluation of parasite number in macrophages or in animals is laborious and renders difficult the screening of several drugs at a time. Luciferase had already been transfected transiently (16), and more recently stably (30), in Leishmania promastigotes. Leishmania promastigotes stably transfected with reporter genes have been used to look at infections of macrophages or animals (27, 30). The possibility of using luciferase-expressing Leishmania amastigotes for

**FIG. 2.** Susceptibility of axenic amastigotes to neomycin and hygromycin B. Results are expressed as the mean of triplicate experiments. □, wild type with G418; ●, WT-pGMaNEOaLUC with G418; ○, wild type with hygromycin B; ●, WT-CLHyg with hygromycin B.

**FIG. 3.** Relationship between number of axenic amastigotes and luciferase activity. Results are given as mean values for three experiments. Amastigotes were counted using a hemacytometer, while the number of RLU was determined as described in Materials and Methods.
drug testing was investigated in this study. In order to achieve this goal, we set up conditions to transfect efficiently DNA into Leishmania axenic amastigotes. Indeed, although Leishmania promastigotes can routinely be transfected, no successful DNA electroporation of Leishmania axenic amastigotes has been reported. By monitoring capacitance and quantity of DNA, we found that we could indeed successfully transform amastigote cells. Conditions differed slightly from those for electroporation of promastigotes, which is usually carried out at 500 mF.

Toxicity of first- (antimonials) and second-line (pentamidine) drugs was determined for both axenic and intracellular amastigotes expressing the luciferase gene. We found that pentamidine was toxic for axenic amastigotes at concentrations in the range of low micromolar concentrations and in the concentration range potentially achieved during chemotherapy (Table 1). This result was in substantial agreement with those previously found using other protocols, like the MTT test (34). Independently of the method used for assessing the number of parasites, pentamidine was found to be significantly less toxic for axenic amastigotes than for intracellular ones. Moreover, the 50% inhibitory concentration for pentamidine was in the same range regardless of whether its determination was done using the luciferase or conventional staining techniques in a number of different cell types (2, 34). Sodium stibogluconate was toxic for both axenic and intracellular amastigotes at concentrations below 100 and 55 μg of Sb/ml, respectively. Using a viability-based test, it has been previously shown that sodium stibogluconate is toxic for axenic amastigotes of L. infantum at concentrations from 24 to 134 μg of Sb/ml (Table 1). We confirmed that intracellular amastigotes were more susceptible to sodium stibogluconate than were extracellular ones, at a concentration of 55 μg/ml in the luciferase assay (Table 1). To compare more adequately those values obtained with staining using the same cell line and the same drug lot, we determined the EC50 by using Giemsa staining to be 35 μg/ml (Table 1). These values are slightly higher than this laboratory's previous determination of 10 μg/ml (32) and other values available in the literature, which are in the range of 10 to 30 μg/ml (20, 29).

The second antimony-containing drug in clinical use, meglumine, was also toxic for intracellular amastigotes at a concentration (95 μg/ml) which was slightly higher than those previously found using other models or methodologies (15, 33). As reported previously (32), meglumine at concentrations as high as 400 μg/ml was not toxic for axenic amastigotes of L. infantum, as previously shown for the same species using counting methods (32). The activity of the trivalent antimony-containing drug potassium antimonyl tartrate was found to be highly toxic for intracellular amastigotes of L. infantum, at a concentration below 1 μg/ml.

Collectively, all these data show that most well-known leishmaniacidal agents, whose activities have been demonstrated in vitro with a macrophage model and are in clinical use, were toxic for both axenic and intracellular amastigotes expressing luciferase activity. This in vitro model presents numerous advantages over the traditional drug-screening procedure: (i) interpretation of the results is easier; and (ii) since the same method is used to measure drug activity against both axenic and intramacrophagic amastigotes, the influence of macrophages on drug activity can now be directly analyzed. The main advantage of the use of luciferase-expressing drug potassium antimonyl tartrate was found to be highly toxic for intracellular amastigotes of L. infantum, at a concentration below 1 μg/ml.

Collectively, all these data show that most well-known leishmaniacidal agents, whose activities have been demonstrated in vitro with a macrophage model and are in clinical use, were toxic for both axenic and intracellular amastigotes expressing luciferase activity. This in vitro model presents numerous advantages over the traditional drug-screening procedure: (i) interpretation of the results is easier; and (ii) since the same method is used to measure drug activity against both axenic and intramacrophagic amastigotes, the influence of macrophages on drug activity can now be directly analyzed. The main advantage of the use of luciferase-expressing parasites is the possibility of determining intracellular infection with and without drugs at a fraction of the time required when using staining methods. This model, which permits us to directly evaluate the toxicity of new compounds directly against the mammalian...
stage of the parasites and to evaluate the role of macrophages in the toxicity has the potential to be automated in 96-well formats for high-throughput screening of drugs. There are, nonetheless, some differences in EC50 determinations, depending on whether the determinations are done using luciferase or staining. One difference is that the luciferase method measures the total number of parasites present, while the staining methods provide an approximation of the macrophages that were counted. Thus, the new methodology may explain the differences between our EC50 determinations, notably for Sb(V) drugs, and the values available in the literature.

Table 1. EC50 determinations in Leishmania sp. axenic and intracellular amastigotes

<table>
<thead>
<tr>
<th>Drug</th>
<th>EC50 Axenic amastigotes</th>
<th>EC50 Intracellular amastigotes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Luc assay</td>
<td>Other methods (source)</td>
</tr>
<tr>
<td>Pentamidine</td>
<td>1.50 ± 0.52 µM</td>
<td>1–3 µM (7, 34)</td>
</tr>
<tr>
<td>Sodium stibogluconate</td>
<td>80 µg Sb/ml</td>
<td>24–134 µg/ml (7, 14, 34)</td>
</tr>
<tr>
<td>Sodium meglumine</td>
<td>&gt;400 µg Sb/ml</td>
<td>1.800 µg/ml (32)</td>
</tr>
<tr>
<td>Sb (III)</td>
<td>ND</td>
<td>4.70 ± 2.4 µg/ml (this study)</td>
</tr>
</tbody>
</table>

a Reference(s) or source of EC50 is shown within parentheses.
b ND, not determined.

REFERENCES